Xilio Therapeutics Implements 1-for-14 Reverse Stock Split to Regain Nasdaq Compliance

summarizeSummary

Xilio Therapeutics, Inc. has officially filed to implement a 1-for-14 reverse stock split, effective March 13, 2026, primarily to meet Nasdaq's minimum bid price requirement.

check_boxKey Events

• Reverse Stock Split Implemented

  Xilio Therapeutics filed a Certificate of Amendment to its Restated Certificate of Incorporation, effecting a 1-for-14 reverse stock split of its common stock, effective March 13, 2026.

• Nasdaq Compliance Objective

  The primary purpose of the reverse stock split is to increase the per-share market price to regain compliance with the Nasdaq Capital Market's minimum bid price requirement.

• Reduction in Outstanding Shares

  The split will reduce the number of outstanding shares from approximately 73.5 million to approximately 5.2 million shares. The number of authorized shares and par value remain unchanged.

• Trading on Split-Adjusted Basis

  The common stock is expected to begin trading on a post-Reverse Stock Split basis at market open on March 16, 2026, under the existing 'XLO' ticker.

auto_awesomeAnalysis

This 8-K formalizes the previously announced 1-for-14 reverse stock split, a critical move for Xilio Therapeutics to regain compliance with Nasdaq's minimum bid price requirement. While necessary for continued listing, reverse stock splits are generally viewed negatively by the market as they often signal underlying financial distress or a lack of investor confidence. The substantial split ratio (1-for-14) indicates the severity of the company's low stock price, which is currently trading below its 52-week low. Investors should monitor the stock's performance post-split and the company's ability to maintain Nasdaq compliance, as well as any further capital raises or operational updates.